At the archive date, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. was expected to release its Q3 2026 10-Q filing on November 3, 2026, before market open. Last quarter: CRL swung to a net loss in Q2 FY2026 as a $63.7 million divestiture charge overshadowed a 19.7% increase in operating income, while cost-saving initiatives and a strategic portfolio overhaul lifted margins.
EPS Estimate
$2.98
Revenue Estimate
$966.74M
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the CRL page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Charles River expects to achieve $300 million in cumulative annualized cost savings by the end of 2026, with over $175 million already benefiting fiscal 2025, driven by workforce optimization, site consolidation, and procurement efficiencies.
The Discovery and Safety Assessment (DSA) segment backlog rose to $2.0 billion as of June 27, 2026 from $1.9 billion at December 27, 2025, indicating a modest recovery in client spending.
The sale-leaseback of assets at the Wilmington, Massachusetts site generated a pre-tax gain of $38.5 million, with $23.2 million allocated to the RMS segment and $15.3 million to unallocated corporate.
Revenue
$1B
-2.72% YoY
EPS (Diluted)
-$0.03
-102.83% YoY
Operating Income
$119.89M
+19.73% YoY
Add CRL to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.